Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally.
Divi's Laboratories Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹5,110.10|
|52 Week High||₹2,985.00|
|52 Week Low||₹5,271.65|
|1 Month Change||6.05%|
|3 Month Change||19.15%|
|1 Year Change||61.77%|
|3 Year Change||275.26%|
|5 Year Change||283.54%|
|Change since IPO||57,886.95%|
Recent News & Updates
With EPS Growth And More, Divi's Laboratories (NSE:DIVISLAB) Is Interesting
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
|DIVISLAB||IN Life Sciences||IN Market|
Return vs Industry: DIVISLAB exceeded the Indian Life Sciences industry which returned 45.3% over the past year.
Return vs Market: DIVISLAB exceeded the Indian Market which returned 59% over the past year.
Stable Share Price: DIVISLAB is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: DIVISLAB's weekly volatility (3%) has been stable over the past year.
About the Company
Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and supplies a range of carotenoids, as well as markets vitamins to nutritional, pharma, food/beverage, and feed industries. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994.
Is Divi's Laboratories undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DIVISLAB (₹5110.1) is trading above our estimate of fair value (₹1328.51)
Significantly Below Fair Value: DIVISLAB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DIVISLAB is poor value based on its PE Ratio (66.2x) compared to the Indian Life Sciences industry average (24.5x).
PE vs Market: DIVISLAB is poor value based on its PE Ratio (66.2x) compared to the Indian market (20.4x).
Price to Earnings Growth Ratio
PEG Ratio: DIVISLAB is poor value based on its PEG Ratio (3.6x)
Price to Book Ratio
PB vs Industry: DIVISLAB is overvalued based on its PB Ratio (14.6x) compared to the IN Life Sciences industry average (4.2x).
How is Divi's Laboratories forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DIVISLAB's forecast earnings growth (18.6% per year) is above the savings rate (6.8%).
Earnings vs Market: DIVISLAB's earnings (18.6% per year) are forecast to grow faster than the Indian market (18.4% per year).
High Growth Earnings: DIVISLAB's earnings are forecast to grow, but not significantly.
Revenue vs Market: DIVISLAB's revenue (16.3% per year) is forecast to grow faster than the Indian market (12.6% per year).
High Growth Revenue: DIVISLAB's revenue (16.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DIVISLAB's Return on Equity is forecast to be high in 3 years time (24.7%)
How has Divi's Laboratories performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DIVISLAB has high quality earnings.
Growing Profit Margin: DIVISLAB's current net profit margins (28.5%) are higher than last year (26.8%).
Past Earnings Growth Analysis
Earnings Trend: DIVISLAB's earnings have grown by 17.7% per year over the past 5 years.
Accelerating Growth: DIVISLAB's earnings growth over the past year (28.4%) exceeds its 5-year average (17.7% per year).
Earnings vs Industry: DIVISLAB earnings growth over the past year (28.4%) underperformed the Life Sciences industry 34.7%.
Return on Equity
High ROE: DIVISLAB's Return on Equity (22%) is considered high.
How is Divi's Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: DIVISLAB's short term assets (₹61.7B) exceed its short term liabilities (₹11.1B).
Long Term Liabilities: DIVISLAB's short term assets (₹61.7B) exceed its long term liabilities (₹3.7B).
Debt to Equity History and Analysis
Debt Level: DIVISLAB's debt to equity ratio (0.05%) is considered satisfactory.
Reducing Debt: DIVISLAB's debt to equity ratio has reduced from 0.9% to 0.05% over the past 5 years.
Debt Coverage: DIVISLAB's debt is well covered by operating cash flow (40309.1%).
Interest Coverage: DIVISLAB earns more interest than it pays, so coverage of interest payments is not a concern.
What is Divi's Laboratories's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DIVISLAB's dividend (0.39%) is higher than the bottom 25% of dividend payers in the Indian market (0.34%).
High Dividend: DIVISLAB's dividend (0.39%) is low compared to the top 25% of dividend payers in the Indian market (1.45%).
Stability and Growth of Payments
Stable Dividend: DIVISLAB's dividends per share have been stable in the past 10 years.
Growing Dividend: DIVISLAB's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (25.9%), DIVISLAB's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: DIVISLAB's dividends in 3 years are forecast to be well covered by earnings (25.7% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kiran Divi (45 yo)
Dr. Kiran Satchandra Divi has been the Chief Executive Officer of Divi's Laboratories Limited since January 4, 2020. Dr. Divi has been an Whole-time Director at Divi's Laboratories Limited and its and ser...
CEO Compensation Analysis
Compensation vs Market: Kiran's total compensation ($USD3.83M) is above average for companies of similar size in the Indian market ($USD1.17M).
Compensation vs Earnings: Kiran's compensation has increased by more than 20% in the past year.
Experienced Management: DIVISLAB's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: DIVISLAB's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DIVISLAB insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Divi's Laboratories Limited's employee growth, exchange listings and data sources
- Name: Divi's Laboratories Limited
- Ticker: DIVISLAB
- Exchange: NSEI
- Founded: 1990
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹1.357t
- Shares outstanding: 265.47m
- Website: https://www.divislabs.com
Number of Employees
- Divi's Laboratories Limited
- Divi Towers
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/20 15:28|
|End of Day Share Price||2021/09/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.